Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation

XPB, a subunit of TFIIH, is a target of the natural product triptolide

(2011) Denis V Titov et al.   Nature Chemical Biology

TRAIL Receptor Signaling Regulation of Chemosensitivity In Vivo but Not In Vitro

(2011) Christina Menke et al.   PLoS One

RNA polymerase – An important molecular target of triptolide in cancer cells

(2010) Jingxuan Pan   CANCER LETTERS

Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation

(2010) Annie Yang et al.   CURRENT OPINION IN CELL BIOLOGY

Ursolic Acid, a Pentacyclin Triterpene, Potentiates TRAIL-induced Apoptosis through p53-independent Up-regulation of Death Receptors

(2010) Sahdeo Prasad et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MAPKs Are Not Involved in Triptolide-Induced Cell Growth Inhibition and Apoptosis in Prostate Cancer Cell Lines with Different p53 Status

(2010) Wei Li et al.   PLANTA MEDICA

Modulating the p53 pathway

(2010) Anwesha Dey et al.   SEMINARS IN CANCER BIOLOGY

Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells

(2009) D. H. Mak et al.   MOLECULAR CANCER THERAPEUTICS

Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA

(2009) S. Vispe et al.   MOLECULAR CANCER THERAPEUTICS

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5

(2008) B. Z. Carter et al.   BLOOD

TRAIL receptor signalling and modulation: Are we on the right TRAIL?

(2008) Devalingam Mahalingam et al.   CANCER TREATMENT REVIEWS

Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer

(2008) Grace L. Lu-Yao   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

p53-Mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells

(2008) F Toscano et al.   ONCOGENE

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

(2008) A. J. Frew et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK

(2008) K. A. Boehme et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA